Google
Apple
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
ASTRAZENECA PLC |
Delayed
Other stock markets
|
|
5-day change | 1st Jan Change | |
| 11102.00 GBX | +0.87% | +0.51% | -1.03% | |
| Sep. 28 | Soaring dollar and oil spooks investors |  |
| Sep. 28 | BioCity Signs Collaboration Agreement with AstraZeneca | CI |
Financials (USD)
| Sales 2023 * | 45,778 M | Sales 2024 * | 50,522 M | Capitalization | 208 B |
|---|---|---|---|---|---|
| Net income 2023 * | 6,472 M | Net income 2024 * | 8,899 M | EV / Sales 2023 * | 5,02x |
| Net Debt 2023 * | 21,552 M | Net Debt 2024 * | 17,026 M | EV / Sales 2024 * | 4,46x |
| P/E ratio 2023 * | 29,8x | P/E ratio 2024 * | 22,3x | Employees | - |
| Yield 2023 * | 2,25% | Yield 2024 * | 2,35% | Free-Float | 96.44% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
More news
| 1 day | +1.21% | ||
| 1 week | +1.07% | ||
| Current month | +4.71% | ||
| 1 month | +3.33% | ||
| 3 months | -0.64% | ||
| 6 months | -0.02% | ||
| Current year | -0.48% |
1 week
10 878.00
11 310.00
1 month
10 366.0011 310.00
Current year
10 020.0012 392.00
1 year
9 499.2112 392.00
3 years
6 736.0012 392.00
5 years
5 312.0012 392.00
10 years
3 106.0012 392.00
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 8.29% | 67 M$ | +13.43% | - | |
| 5.39% | 162 M$ | +13.10% | ||
| 5.17% | 30 M$ | +5.20% | - | |
| 4.89% | 656 M$ | +8.11% | ||
| 3.47% | 193 M$ | +4.24% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 23-09-29 | 11102.00 | +0.87% | 1 571 473 |
| 23-09-28 | 11006.00 | -1.01% | 1,491,439 |
| 23-09-27 | 11118.00 | -0.41% | 1,501,178 |
| 23-09-26 | 11164.00 | -0.27% | 1,606,820 |
| 23-09-25 | 11194.00 | +1.34% | 3,471,176 |
Delayed Quote London Stock Exchange, September 29, 2023 at 03:40 am EDT
More quotes
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (96.9%). Net sales break down by treatment area between oncology (34%), cardiovascular, renal and metabolic diseases (21.4%), respiratory and autoimmune diseases (13.4%), and other (31.2%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (3.1%).
Net sales are distributed geographically as follows: the United Kingdom (7%), Europe (20.1%), Americas (44.2%) and Africa/Asia/Australia (28.7%).
Sector
Pharmaceuticals
Calendar
2023-09-28
- Citi European HC Bus Trip
Trading Rating :
Investor Rating :
ESG Refinitiv :
B+
Sell
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
134.33USD
Average target price
170.39USD
Spread / Average Target
+26.84%
EPS Revisions
| 1st Jan change | Capi. (M$) | |
|---|---|---|
| -0.48% | 208 B $ | |
| +12.45% | 212 B $ | |
| -13.43% | 220 B $ | |
| -37.37% | 181 B $ | |
| -5.99% | 265 B $ | |
| -5.79% | 269 B $ | |
| +3.11% | 145 B $ | |
| +11.73% | 133 B $ | |
| -19.19% | 121 B $ | |
| -12.15% | 93 974 M $ |
